PRG-2311
/ Pregene Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 11, 2024
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Tongji Hospital
CAR T-Cell Therapy • New P1 trial • Glomerulonephritis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
1 to 1
Of
1
Go to page
1